The Albumin in Acute Stroke (ALIAS) Multicenter Clinical Trial: Safety Analysis of Part 1 and Rationale and Design of Part 2

enrollment in the Albumin in Acute Stroke (ALIAS) Trial was suspended in late 2007 due to a safety concern. We present the safety data of that Trial ("Part 1") and the rationale for the design of Part 2. ALIAS Part 1 was designed to assess whether 25% albumin (ALB) started within 5 hours o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2011-01, Vol.42 (1), p.119-127
Hauptverfasser:	GINSBERG, Myron D, PALESCH, Yuko Y, MARTIN, Renee H, HILL, Michael D, MOY, Claudia S, WALDMAN, Bonnie D, YEATTS, Sharon D, TAMARIZ, Diego, RYCKBORST, Karla
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Biological and medical sciences Cohort Studies Diuretics - administration & dosage Female Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Serum Albumin - administration & dosage Serum Albumin - adverse effects Stroke - blood Stroke - mortality Stroke - therapy Thrombolytic Therapy Time Factors Troponin - blood Vascular diseases and vascular malformations of the nervous system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!